The regulatory and reimbursement landscape for perineural therapy has evolved significantly as clinical evidence accumulates and professional societies establish standards for training, technique, and outcome documentation. The U.S. Food and Drug Administration regulates the therapeutic agents used in perineural injections—dextrose, local anesthetics, corticosteroids, and biologics—rather than the procedure itself, with most agents approved for general injection use when administered by qualified practitioners. The FDA's 361 HCT/P regulations govern minimally manipulated autologous biologics including platelet-rich plasma and adipose-derived stem cells, allowing their use in perineural therapy under physician discretion without requiring biologics license applications. Allogeneic biologics including amniotic fluid and umbilical cord products face stricter regulatory scrutiny, with the FDA issuing warning letters to manufacturers making unsubstantiated claims and requiring investigational new drug applications for certain products. Over 24 FDA enforcement actions related to perineural biologic products were taken in 2025, reflecting ongoing regulatory refinement.

The Centers for Medicare and Medicaid Services (CMS) and commercial payers determine reimbursement for perineural therapy through CPT coding and coverage policies. Perineural Therapy Market research indicates that CPT codes exist for peripheral nerve injections (64450), trigger point injections (20552), and various other injection procedures that may be applied to perineural therapy depending on documentation and payer interpretation. However, specific coding for dextrose prolotherapy and biologic perineural injections remains limited, creating reimbursement variability and administrative burden for providers. Over 45% of perineural therapy practices reported reimbursement challenges as a significant barrier to market growth in 2025. Workers' compensation programs have been more receptive to perineural therapy coverage, particularly for carpal tunnel syndrome and occupational overuse injuries where non-surgical alternatives reduce disability duration and claim costs.

Professional society guidelines are progressively recognizing perineural therapy, with the American Association of Orthopedic Medicine, the American Academy of Physical Medicine and Rehabilitation, and the World Institute of Pain publishing position statements and technique guidelines. The American Medical Association's House of Delegates has considered resolutions supporting prolotherapy research and appropriate coverage. State medical boards regulate scope of practice for perineural injections, with most states permitting trained physicians, osteopaths, and advanced practice providers to perform these procedures. Malpractice insurance considerations vary by carrier and jurisdiction, with some insurers requiring additional training documentation for biologic injections. The standardization of training curricula, the accumulation of high-quality clinical trial data, and the development of indication-specific CPT codes are critical enablers of reimbursement expansion. As outcome registries demonstrate cost-effectiveness and as professional guidelines strengthen, perineural therapy is transitioning from alternative medicine status to recognized interventional procedure with predictable coverage and sustainable practice economics.

Q1: How does the FDA regulate perineural therapy agents? The FDA regulates injection agents rather than procedures, with 361 HCT/P rules governing autologous biologics and stricter oversight for allogeneic products, including 24 enforcement actions in 2025.

Q2: What reimbursement challenges exist for perineural therapy? Limited specific CPT codes for dextrose prolotherapy and biologic injections create variability, with 45% of practices reporting reimbursement as a significant growth barrier.

Q3: What professional guidelines support perineural therapy? The American Association of Orthopedic Medicine, AAPMR, and World Institute of Pain publish technique guidelines, while workers' compensation programs increasingly cover occupational injury applications.